Maria Fleseriu1. 1. Department of Medicine, Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon 97239, USA. fleseriu@ohsu.edu
Abstract
PURPOSE OF REVIEW: This review focuses on combination drug treatment for acromegaly patients, including novel concepts and experimental therapies, with an emphasis on the author's personal experience. RECENT FINDINGS: A review of published clinical studies demonstrates that combination therapy; somatostatin receptor ligands and dopamine agonists, somatostatin receptor ligands and pegvisomant, or cabergoline and pegvisomant could provide significant additive biochemical control of acromegaly in patients inadequately controlled with conventional somatostatin receptor ligand therapy. SUMMARY: Advances in combination medical therapy have opened up new perspectives for acromegaly patients who are poorly, or nonresponsive to, presently available single drug therapies.
PURPOSE OF REVIEW: This review focuses on combination drug treatment for acromegalypatients, including novel concepts and experimental therapies, with an emphasis on the author's personal experience. RECENT FINDINGS: A review of published clinical studies demonstrates that combination therapy; somatostatin receptor ligands and dopamine agonists, somatostatin receptor ligands and pegvisomant, or cabergoline and pegvisomant could provide significant additive biochemical control of acromegaly in patients inadequately controlled with conventional somatostatin receptor ligand therapy. SUMMARY: Advances in combination medical therapy have opened up new perspectives for acromegalypatients who are poorly, or nonresponsive to, presently available single drug therapies.
Authors: A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2017-02-07 Impact factor: 4.256